Corona Outbreak: Is Remdesivir the ray of hope for COVID-19 patients?

U.S. researchers have expressed hope for an experimental drug Remdesivir in the fight against coronavirus. A clinical trial of the drug has shown that patie
nts recover 30 percent faster. The news agency AFP says this is the first evidence of successful treatment for new diseases.

According to a CNN report, the researchers delivered some good news on Wednesday about the probable therapy of coronavirus. There is available data that experimental drug, Remdesivir, can help recover quickly from COVID-19.
Corona Outbreak: Is Remdesivir the ray of hope for COVID-19 patients

The New York Times, reports that the US Food and Drug Administration (FDA) has not yet approved any drugs to treat coronavirus. However, the FDA intends to make an announcement for emergency use. A senior administration official was quoted as saying that the statement of approval could reach by Wednesday.

The FDA told CNN that, they had communicated with Gilead Sciences, the manufacturer of Remdesivir, about developing a drug to give to the patients. A US government-funded study found that victims, treating with Remdesivir, recovered faster than normal patients.

Anthony S. Fauci, the top infectious disease expert of the country and director of the National Institute of Allergy and Infectious Diseases in the United States, was already confident about the positive results. Yesterday, in a meeting with US President Donald Trump at the White House, Fauci said that, the data demonstrated that the positive effects of Remdesivir on COVID-19 to a rapid recovery were clear.

Preliminary results have indicated that the recovery time from the application of Remdesivir has come down from 15 days to 11 days. This is quite comparable to the effects of the influenza drug Tamiflu, in case of common flu. "While 31 per cent is not very much in the place of 100 percent development, it is a very significant proof of the concept," Fauci said. This can lessen the risk of death. '
Corona Outbreak: Is Remdesivir the ray of hope for COVID-19 patients

Earlier, tests did not usually reveal data about the potency of the drug. But Fauci said that since there was clear evidence that the drug was working, it quickly fell into the moral obligation to inform people.

In the words of Rajesh T. Gandhi, an infectious disease specialist at Massachusetts General Hospital, "You have to keep your feet out the door during this war. And that's for sure, it's a very good first step. "Rajesh is also a professor at Harvard Medical School. He is very excited about the discovery of anti-viral.

"Early results are so favourable for treatment that we are quite optimistic about this antiviral," he said. Corona-therapy will help us understand much more than we are in the situation we are in today.

But not everyone is so excited about this anti-viral. Eric Tople is the director of the Scripps Research Transitional Institute in La Jolla, California. "It's not a breakthrough drug," he said. All in all, there is a lot of fog. I’m still confused. ”He added,“ But that’s right, it’s great as a start. And safe. "
Corona Outbreak: Is Remdesivir the ray of hope for COVID-19 patients

According to George Thompson, an infectious disease specialist at the University of California, Davis Medical Center, the drug is injected directly into the bloodstream through IV. It breaks down an enzyme called 'RNA polymerase' in the body. Many viruses utilize these enzymes to replicate themselves. As the patient's condition was critical, physicians were able to obtain permission from the FDA to use this antidote without any clinical trial.

Further investigation is required in the case of ‘Remdesivir’. Among the limited drugs that are being tested against COVID-19 are the ones that are being tested according to the guidelines, with the goal of getting FDA approval. Internationally, 1,090 people took part in it.

The World Health Organization did not instantly respond to a request for comment. Corona response team technical chief, Dr Maria Van Kerkhove said, ‘ Usually, you don’t have a study that will become a game-changer when it will be published. The organisation usually gathers proofs from a number of studies before reviewing and criticizing the evidence.

Andre Kalil, the chief behind the clinical trial, told CNN yesterday that, this drug is not the end of the story when it comes to treating COVID-19. More work needs to be done. Need to find another treatment. This test will also continue. He thinks, ‘It is also crucial to stay in the hospital for a short period. The longer, the patient will stay, the more complication increases.
Corona Outbreak: Is Remdesivir the ray of hope for COVID-19 patients

Gilead Sciences disclosed its own outcomes from a separate experiment of the drug yesterday. They announced that those who took it for 5 days showed good outcome, as those who took it for 10 days. However, the test did not indicate whether it was helpful in treating the virus. More evidence has to be presented. The test was conducted on 398 critically ill patients. A spokesman for the company said: "Our goal was related to using it for 5 days or 10 days ."

According to the US health-related website State News, critically ill Covid-19 victims are being treated at Chicago hospital in the United States with Gilead Sciences' antiviral drug, Remdesivir. Intensive clinical trials have shown that patients recover faster from fever and shortness of breath and release all patients in less than a week.
In that test, two methods of treatments were being sought with Remdesivir. One is for 5 days treatment and another is for 10 days. The primary goal was to make a statistical comparison of patients' improvement between the two medical approaches. Improvement was measured on a seven-point scale with the worst point of the scale being death and the best result being discharged from the hospital. In addition, the supply of oxygen at different stages was also on the scale. However, the lack of regulation in this study may make it difficult to explain the results.

The drug is being tested on 2,400 patients in 152 places around the world who have severe symptoms. In addition, the drug is being tested in 1,700 patients in 189 hospitals around the world who have moderate symptoms.
Corona Outbreak: Is Remdesivir the ray of hope for COVID-19 patients

An AFP report asserts a small-scale trial published last week by the World Health Organization (WHO) found that Remdesivir against the Ebola virus was ineffective. In addition, in the case of the Covid-19, which originated in Wuhan, China in December last year, the limited effects of Remdesivir were also observed.

Meanwhile, a report from Nature Magazine, explained that Remdesivir was one of the first drugs identified in the laboratory as likely to affect the novel coronavirus SARS-CoV-2, which is responsible for the outcome of COVID-19. Despite the conflicting data available, the fastest-growing treatment as the largest test result will build up as a standard of care in the United States.

Remdesivir interferes the replication of some viruses, including the SARS-CoV-2 virus, which is responsible for the current epidemic.

The news came a few weeks after the information was leaked and a day after the mixed results of clinical trials of the drug. A small test in China reportedly did not work. However, experts were optimistic about the large-scale controlled trial in the United States.

In February, researchers showed that the drug curtails viral infections in human cells that grow in a laboratory.

The World Health Organization's emergency committee is set to discuss the evolution of the COVID-19 epidemic for the first time in three months on Thursday, which killed more than 226,000 people worldwide, the AFP news agency reported.

While Anthony S. Fauci spoke of the positive aspects of the study.
Michael Ryan, a senior official at the World Health Organization, declined to consider the latest study, saying he had not reviewed the entire study. "We are all hopeful that one or more treatments currently being monitored or tested will yield results and reduce deaths," Ryan said.

Gilead began to increase the production of Remdesivir even before the NIAID results. By the end of March, the company had produced enough to treat 30,000 patients. By simplifying its production process and finding new sources of raw materials, Gilead has announced that by the end of the year, it will have produced enough Remdesivir to treat more than one million people.
U.S. researchers have praised the potential progress in the fight against coronavirus by showing patients response to antiviral drugs after the experiment. Despite rising deaths or unusual economic figures, global hopes for a return to normal are rising.

Remdisivir, a drug developed by Gilead Sciences, had earlier had some success in treating Ebola. However, coronavirus, which is the cause of Covid-19 disease, has shown good success in preventing and treating the virus. Scientists have had significant success, especially in applying the drug to other animals. Last February, the World Health Organization (WHO) also mentioned Remdesivir as a potential drug for the treatment of Covid-19.

According to the result of a phase III trial from Gilead, Remdesivir was normally well-tolerated in both the 5-day and 10-day medication groups. The most familiar adverse events arising in more than 10 percent of patients in either group were nausea (5-day: 10.0%, n=20/200 vs. 10-day: 8.6%, n=17/197) and acute respiratory failure (5-day: 6.0%, n=12/200 vs. 10-day: 10.7%, n= 21/197). Grade 3 or higher liver enzyme (ALT) elevations occurred in 7.3 percent (n=28/385) of patients, with 3.0 per cent (n=12/397) of patients discontinuing remdesivir therapy owing to elevated liver tests.

Stephen Griffin, a virologist at the University of Leeds in the UK, said there was a lot of focus on Remdesivir because it was the most important discovery so far. It is not a miracle medicine that everyone is looking for. But if it saves some people from complicated situations, it is good enough.

Post a Comment